{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:52:14Z","timestamp":1784371934629,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["5.822"],"award-info":[{"award-number":["5.822"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jhep.2023.04.027","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T20:55:12Z","timestamp":1682628912000},"page":"657-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6340-8685","authenticated-orcid":false,"given":"Julius","family":"Hollnberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savrina","family":"Manhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aeschbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmineh","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Shornikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Manuilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithika","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-6132","authenticated-orcid":false,"given":"Roberto","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Maiorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.04.027_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2009.01.004","article-title":"Hepatitis D: thirty years after","volume":"50","author":"Rizzetto","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/jvi.67.1.366-372.1993","article-title":"Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion","volume":"67","author":"Sureau","year":"1993","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2023.04.027_bib3","doi-asserted-by":"crossref","first-page":"a021568","DOI":"10.1101\/cshperspect.a021568","article-title":"Hepatitis D virus replication","volume":"5","author":"Taylor","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2023.04.027_bib4","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate co-transporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.jhep.2023.04.027_bib5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.04.027_bib6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/jvi.63.5.1945-1950.1989","article-title":"Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen","volume":"63","author":"Kuo","year":"1989","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2023.04.027_bib7","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/jvi.67.12.7659-7662.1993","article-title":"Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen","volume":"67","author":"Hwang","year":"1993","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2023.04.027_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib9","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains","volume":"66","author":"Le Gal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.04.027_bib10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268818001942","article-title":"Hepatitis delta virus and hepatocellular carcinoma: an update","volume":"146","author":"Romeo","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jhep.2023.04.027_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"Beguelin","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib13","first-page":"967","article-title":"Standard and pegylated interferon therapy of HDV infection: a systematic review and meta-analysis","volume":"17","author":"Alavian","year":"2012","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1016\/j.jhep.2023.04.027_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.04.027_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.04.027_bib16","series-title":"First drug for hepatitis D has been approved by European Commission","year":"2020"},{"key":"10.1016\/j.jhep.2023.04.027_bib17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.04.027_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years\u2019 bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00103-022-03486-2","article-title":"Bulevirtide als erster spezifischer Wirkstoff gegen Hepatitis-D-Virusinfektionen, Mechanismus und klinische Wirkung","volume":"65","author":"Nkongolo","year":"2022","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"10.1016\/j.jhep.2023.04.027_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with\u00a0tenofovir disoproxil fumarate in patients with hepatitis B virus\u00a0and\u00a0hepatitis D virus coinfection (MYR202): a multicentre, randomised,\u00a0parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jhep.2023.04.027_bib23","first-page":"26","article-title":"Bulevirtide-based treatment strategies\u00a0for chronic hepatitis delta: a review","volume":"30","author":"Degasperi","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2023.04.027_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13831","article-title":"Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA","author":"Deterding","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2023.04.027_bib25","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(22)00433-0","article-title":"Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study","volume":"77","author":"Wedemeyer","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib26","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41467-019-10117-z","article-title":"Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in\u00a0vivo","volume":"10","author":"Perez-Vargas","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.04.027_bib27","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1128\/JVI.03540-12","article-title":"Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate co-transporting polypeptide","volume":"87","author":"Yan","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2023.04.027_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.21112","article-title":"Characterization of a hepatitis B and hepatitis delta virus receptor binding site","volume":"43","author":"Engelke","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.04.027_bib29","first-page":"e6","article-title":"Analysis of liver biopsies reveals a strong intrahepatic reduction of HDV and inflammatory markers after treatment with Myrcludex B in combination with Tenofovir in chronic HBV\/HDV infected patients","volume":"57","author":"Allweiss","year":"2019","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2023.04.027_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2017-314713","article-title":"Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in\u00a0vitro and in\u00a0vivo","volume":"68","author":"Giersch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.04.027_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis\u00a0D virus-induced interferon response and administered interferons\u00a0control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib32","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2020.11.032","article-title":"New insights into HDV persistence: the role of interferon response and implications for upcoming novel therapies","volume":"74","author":"Zhang","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib33","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.027_bib34","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/v12111334","article-title":"Interplay between Hepatitis D virus and the interferon response","volume":"12","author":"Zhang","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2023.04.027_bib35","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.04.027_bib36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients\u00a0with\u00a0bulevirtide-results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823003136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823003136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:46:38Z","timestamp":1778730398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823003136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0168827823003136"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.04.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}